Results 41 to 50 of about 25,757 (158)

Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia

Haematologica, 2016
Disease relapse is the most common cause of treatment failure after allogeneic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndromes, yet treatment options for such patients remain extremely limited.
Charles Craddock, Myriam Labopin, Marie Robin, Juergen Finke, Patrice Chevallier, Ibrahim Yakoub-Agha, Jean Henri Bourhis, Henrik Sengelov, Didier Blaise, Thomas Luft, Michael Hallek, Nicolaus Kröger, Arnon Nagler, Mohamad Mohty   +13 more
doaj   +1 more source

Familial myelodysplastic syndromes: a review of the literature

Haematologica, 2011
Familial cases of myelodysplastic syndromes are rare, but are immensely valuable for the investigation of the molecular pathogenesis of myelodysplasia in general.
Elena Liew, Carolyn Owen
doaj   +1 more source

Myelodysplastic syndromes: Classification

Journal of Applied Hematology, 2014
The updated WHO classification system for myelodysplastic syndromes (MDS) includes some new entities, in particular "refractory cytopenias with unilineage dysplasia (RCUD)". The following review article presents a short overview regarding all subvariants
Hans Peter Horny
doaj   +1 more source

Rare occurrence of DNMT3A mutations in myelodysplastic syndromes

Haematologica, 2011
Gene mutations and epigenetic changes have been shown to play significant roles in the pathogenesis of myelodysplastic syndromes. Recently, mutations in DNMT3A were identified in 22.1% of patients with acute myeloid leukemia.
Felicitas Thol, Claudia Winschel, Andrea Lüdeking, Haiyang Yun, Inna Friesen, Frederik Damm, Katharina Wagner, Jürgen Krauter, Michael Heuser, Arnold Ganser   +9 more
doaj   +1 more source

Recombinant human erythropoietin plus all-trans retinoic acid and testosterone undecanoate for the treatment of anemia in patients with lower-risk myelodysplastic syndromes: a multicenter, single-arm, prospective trial

Haematologica
Erythropoiesis-stimulating agents (ESAs) achieve hematological improvement-erythroid (HIE) in only 30% of ESA-naïve lower risk myelodysplastic syndrome (LR-MDS) patients with anemia, highlighting the need for developing novel drugs or new treatment ...
Chen Mei, Gaixiang Xu, Cuiping Zheng, Yaping Xie, Minming Li, Yanping Shao, Rongxin Yao, Shi Tao, Wei Jiang, Jun Guo, Zhiyin Zheng, Wei Wang, Xinping Zhou, Liya Ma, Li Ye, Yingwan Luo, Chunmei Yang, Wenjuan Yu, Wanzhuo Xie, Jie Jin, Hongyan Tong   +20 more
doaj   +1 more source

Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes

Haematologica, 2012
Background Reductions in transfusion requirements/improvements in hematologic parameters have been associated with iron chelation therapy in transfusion-dependent patients, including those with myelodysplastic syndromes; data on these reductions ...
Norbert Gattermann, Carlo Finelli, Matteo Della Porta, Pierre Fenaux, Michael Stadler, Agnes Guerci-Bresler, Mathias Schmid, Kerry Taylor, Dominique Vassilieff, Dany Habr, Andrea Marcellari, Bernard Roubert, Christian Rose   +12 more
doaj   +1 more source

Factors implicated in underutilization and poor persistence with hypomethylating agent therapy in myelodysplastic syndromes and chronic myelomonocytic leukaemia in Pakistan

Journal of the Pakistan Medical Association
Objective: To assess the clinical and non-clinical factors leading to non-compliance or discontinuation of hypomethylating agent therapy in patients of myelodysplastic syndromes and chronic myelomonocytic leukaemia.
Zoya Ziad, Aisha Arshad, Laraib Majeed, Muhammad Nizamuddin, Aisha Jamal, Quratulain Rizvi, Nida Anwar   +6 more
doaj   +1 more source

The small population of PIG-A mutant cells in myelodysplastic syndromes do not arise from multipotent hematopoietic stem cells

Haematologica, 2012
Background Patients with paroxysmal nocturnal hemoglobinuria harbor clonal glycosylphosphatidylinositol-anchor deficient cells arising from a multipotent hematopoietic stem cell acquiring a PIG-A mutation.
Jeffrey J. Pu, Rong Hu, Galina L. Mukhina, Hetty E. Carraway, Michael A. McDevitt, Robert A. Brodsky   +5 more
doaj   +1 more source

Genetic features of myelodysplastic syndrome and aplastic anemia in pediatric and young adult patients

Haematologica, 2016
The clinical and histopathological distinctions between inherited versus acquired bone marrow failure and myelodysplastic syndromes are challenging.
Siobán B. Keel, Angela Scott, Marilyn Sanchez-Bonilla, Phoenix A. Ho, Suleyman Gulsuner, Colin C. Pritchard, Janis L. Abkowitz, Mary-Claire King, Tom Walsh, Akiko Shimamura   +9 more
doaj   +1 more source

Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group

Haematologica, 2017
Current recommendations for diagnosing myelodysplastic syndromes endorse flow cytometry as an informative tool. Most flow cytometry protocols focus on the analysis of progenitor cells and the evaluation of the maturing myelomonocytic lineage.
Theresia M. Westers, Eline M.P. Cremers, Uta Oelschlaegel, Ulrika Johansson, Peter Bettelheim, Sergio Matarraz, Alberto Orfao, Bijan Moshaver, Lisa Eidenschink Brodersen, Michael R. Loken, Denise A. Wells, Dolores Subirá, Matthew Cullen, Jeroen G. te Marvelde, Vincent H.J. van der Velden, Frank W.M.B. Preijers, Sung-Chao Chu, Jean Feuillard, Estelle Guérin, Katherina Psarra, Anna Porwit, Leonie Saft, Robin Ireland, Timothy Milne, Marie C. Béné, Birgit I. Witte, Matteo G. Della Porta, Wolfgang Kern, Arjan A. van de Loosdrecht   +28 more
doaj   +1 more source